Drug Discovery World
AUGUST 3, 2023
This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, and “ Why a recent advancement is a giant leap for human genomics ”. Listen here: The post New podcast on the future for genomics and big data appeared first on Drug Discovery World (DDW).
pharmaphorum
OCTOBER 12, 2022
AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. The genomic medicine journey.
pharmaphorum
DECEMBER 9, 2022
The PharmaStars accelerator was set up last year to help bridge the gap between digital health start-ups and potential pharma partners, which can be instrumental in making sure their technologies meet their potential – and help them to navigate the challenges of developing them in the highly regulated healthcare environment.
Drug Discovery World
FEBRUARY 6, 2024
Biopharma and biotech companies without these capabilities are keen to harness these technologies and the number of strategic partnerships with such companies is accelerating at an unprecedented rate. Automation is also being applied to genomics sample preparation, an area that requires particular robustness and scalability.
Drug Discovery World
JANUARY 3, 2023
Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. This makes a TPD-DEL workflow quite efficient.
Drug Discovery World
JANUARY 21, 2024
He has founded and led three bio-AI technology companies, each of which led revolutions in medicine, genomics, agriculture, and conservation. Is pharma’s commercial model dying? He holds more than 15 patents, has over 150 peer-reviewed publications, delivered more than 110 invited talks, and co-founded four companies.
Expert insights. Personalized for you.
52 
Let's personalize your content